Danielle Ternyila

A look back at all the FDA news that happened in the month of November 2018, including several new approvals, priority reviews, a fast track designation, and an accelerated approval, across a variety of cancer types.

Srdan Verstovsek, MD, PhD, discusses the second-line use of ruxolitinib in patients with in PV and additional benefits with the agent as more data become available.

Patients with acute myeloid leukemia now have more treatment options available than ever, due to some major changes to the field over the last year. With 2 drugs already approved for patients with <em>IDH</em> mutations and 4 new drugs expected to receive approval in the next year, it is a more hopeful time than ever for this patient population.

Petros Grivas, MD, PhD, discusses recent immunotherapy advancements in bladder cancer and ongoing research in the field.

Al B. Benson III, MD, FACP, FASCO,&nbsp;discusses the treatment landscape for advanced and metastatic CRC and how molecular profiling can play a vital role in selecting the optimal treatment plan for each patient. He also emphasizes the importance of participation in clinical trials to further understand these patients.

Ben George, MD,&nbsp;discusses the findings from the phase III TAGS study and how these data can impact the treatment landscape of metastatic gastric cancers.

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;October 2018, including several new FDA approvals, priority reviews, a breakthrough therapy designation, and more, in a variety of cancer types.<br /> &nbsp;

Simon Rule, MD, PhD,&nbsp;discusses the treatment options available for younger, fit patients with MCL, including the watch-and-wait approach and BTK inhibitors. He also highlights several clinical trials supporting these strategies, as well as other ongoing trials aiming to advance the treatment landscape for the older patient population.

Robyn M. Scherber, MD, MPH, discusses the prevalence of ruxolitinib failure and how it can be managed in patients with MF. She also highlights combinations and other treatment regimens currently under investigation for this patient population.

Abdulraheem Yacoub, MD,&nbsp;discusses how to manage patients with polycythemia vera after failure on hydroxyurea and some of the upcoming treatment options for this patient population on the horizon.

Padmanee Sharma, MD, PhD,&nbsp;discusses the development of checkpoint inhibitors in several cancers, including urothelial carcinoma, RCC, and prostate cancer. She also addresses the challenges in resistance to these agents and where some clinical trials are moving forward in the field.

Ulka Vaishampayan, MD,&nbsp;discussed the data reported from the phase Ib JAVELIN Solid Tumor trial at the ESMO 2018 Congress and addressed how these data will affect the treatment landscape for patients with advanced RCC.

In an interview with&nbsp;<em>Targeted Oncology,&nbsp;</em>Brian I. Rini, MD, discussed these core findings from the IMmotion 151 trial he presented at the conference, as well as the implications of these findings in RCC moving forward.

Marcia S. Brose, MD, PhD,&nbsp;discussed the clinical benefit of larotrectinib in treating patients with&nbsp;<em>TRK</em> fusion&ndash;positive papillary thyroid cancer.

Michael Wang, MD,&nbsp;discusses the latest options for patients with relapsed MCL, while also addressing some of the challenges with these agents.

Hassane M. Zarour, MD,&nbsp;discussed the research surrounding manipulation of the gut microbiome to improve response to immunotherapy in melanoma and other tumor types.

Infographic: Here, we share the top 5 oncology news stories we reported this week, including the most recent FDA updates and expert insights on key developments in the field.

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;September 2018, including several new approvals, priority reviews, a breakthrough therapy designation, and more, in a variety of cancer types.

Pontchartrain Cancer Center was founded in 2005 to serve an area of Louisiana that lacked the necessary resources for cancer care. This community cancer center, with 2 locations in Southeast Louisiana, accommodates any patient to walk through its doors, filling a major unmet need for the community in this rural area.

In an interview with&nbsp;<em>Targeted Oncology</em>, Katy Rezvani, MD, discussed the potential she sees with CAR NK cells. She also highlighted some of the challenges with both CAR T-cell therapy in patients with CLL, as well as challenges to overcome with CAR NK cells in this patient population.

In an interview with&nbsp;<em>Targeted Oncology</em>, Jorge E. Cortes, MD, discussed the results from the QuANTUM-R trial, as well as some other studies investigating the use of quizartinib in different patient populations in AML.

In an interview with&nbsp;<em>Targeted Oncology</em>, Abou-Alfa discussed those clinical trials and other investigated treatment options for patients with hepatocellular carcinoma. He also highlighted his hopes for the future of this disease.

Paolo A. Ascierto, MD, discusses&nbsp;results from the COLUMBUS trial and sheds light on how physicians can use these findings when choosing treatments for their patients. He also shared his insights on the CheckMate 238 trial investigating nivolumab in the adjuvant setting.

According to findings from the CheckMate-032 trial, clinically meaningful and durable antitumor activity was found with nivolumab (Opdivo) alone and nivolumab plus ipilimumab in heavily-pretreated patients with esophagogastric cancer.

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;August 2018, including several new approvals, a priority review, breakthrough therapy designations, and more in a variety of cancer types.

Sai-Hong Ignatius Ou, MD, PhD,&nbsp;discusses the ALK inhibitors that are currently available for the treatment of <em>ALK</em>-positive NSCLC, as well as ongoing research in this space. He also sheds light on optimal sequencing strategies with these available agents.<br /> &nbsp;

In an interview with&nbsp;<em>Targeted Oncology&nbsp;</em>during the2nd Annual Live Medical Crossfire: Hematologic Malignancies meeting, Alexander M. Lesokhin, MD, assistant attending physician in the Department of Medicine and Myeloma Service at Memorial Sloan Kettering Cancer Center, discussed the current treatment landscape of multiple myeloma and where he predicts the field will be in the next decade. He also shared his thoughts on the current research in CAR T-cell therapy.

In an interview with <em>Targeted Oncology</em><em>,</em> Levy discusses the agents currently being investigated for patients with <em>ROS1</em>- or <em>TRK</em>-rearranged lung cancer. He also highlights the challenges physicians will need to overcome to best treat their patients based on these new findings.

The Gene Upshaw Memorial Tahoe Forest Cancer Center has established a cancer care model to address disparities in lung cancer in rural areas. By partnering with the UC Davis Comprehensive Cancer Center and their UC Davis Cancer Care Network, they have been able to address a large issue in cancer care, where 20% of the American population is living in a rural area without access to a National Cancer Institute-designated cancer center.

Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discussed the results from these 2 analyses in this high-risk patient population with RCC compared to metastatic RCC. He also shares his own insights on what to take away from this data.